COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 13 institutions in 1 country.
Carola BerkingDepartment of Dermatology, Uniklinikum Erlangen, Comprehensive Cancer Center Erlangen-European Metropolitan Region Nürnberg, Friedrich-Alexander University (FAU), 91054 Erlangen, Germany.ORCID 0000-0003-0229-8931
Elisabeth LivingstoneDepartment of Dermatology, University Hospital Essen, and German Cancer Consortium (DKTK), Partner Site Essen, 45147 Essen, Germany.ORCID 0000-0001-8279-9239
Dirk DebusDepartment of Dermatology, Nuremberg General Hospital-Paracelsus Medical University, 90419 Nuremberg, Germany.
Carmen LoquaiDepartment of Dermatology, Klinikum Bremen-Ost, Gesundheit Nord gGmbH, 28205 Bremen, Germany.
Michael WeichenthalDepartment of Dermatology, Skin Cancer Center, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.ORCID 0000-0002-9060-4961
Ulrike LeiterDepartment of Dermatology, University Hospital Tuebingen, 72076 Tuebingen, Germany.ORCID 0000-0002-8019-1577
Felix KieckerDepartment of Dermatology and Venereology, Vivantes Klinikum Berlin Neukölln, 12351 Berlin, Germany.
Peter MohrDepartment of Dermatology, Elbe Kliniken Buxtehude, 21614 Buxtehude, Germany.
Thomas K EigentlerDepartment of Dermatology and Allergy, Skin Cancer Center Charité, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Markus V HepptDepartment of Dermatology, Uniklinikum Erlangen, Comprehensive Cancer Center Erlangen-European Metropolitan Region Nürnberg, Friedrich-Alexander University (FAU), 91054 Erlangen, Germany.ORCID 0000-0003-4603-1825
Imke von WasielewskiDepartment of Dermatology, Skin Cancer Center Hannover, Hannover Medical School, 30625 Hannover, Germany.
Dirk SchadendorfDepartment of Dermatology, University Hospital Essen, and German Cancer Consortium (DKTK), Partner Site Essen, 45147 Essen, Germany.ORCID 0000-0003-3524-7858
Ralf GutzmerDepartment of Dermatology, Johannes Wesling Medical Center, Ruhr University Bochum, 44801 Minden, Germany.ORCID 0000-0001-7921-2820
Comprehensive Cancer Center Erlangen · DENovartis (Germany) · DECharité - Universitätsmedizin Berlin · DEElbe Kliniken Stade-Buxtehude · DEEssen University Hospital · DEJohannes Wesling Klinikum Minden · DEKlinikum Bremen-Mitte · DEMedizinische Hochschule Hannover · DENational Center for Tumor Diseases · DENuremberg Hospital · DEUniversity Hospital Schleswig-Holstein · DEUniversity of Tübingen · DEVivantes Klinikum · DE
Funding
Novartis Pharma GmbH Germany restricted
6 · The paper itself
Abstract
Combined BRAF/MEK-inhibition constitutes a relevant treatment option for
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma. · full record | OpenQuestion